The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.